KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $155.1 million.

  • Recursion Pharmaceuticals' Total Current Liabilities rose 4244.27% to $155.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.1 million, marking a year-over-year increase of 4244.27%. This contributed to the annual value of $187.5 million for FY2024, which is 10121.28% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Total Current Liabilities stood at $155.1 million, which was up 4244.27% from $164.0 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Total Current Liabilities ranged from a high of $187.5 million in Q4 2024 and a low of $26.9 million during Q1 2021
  • Moreover, its 5-year median value for Total Current Liabilities was $93.2 million (2023), whereas its average is $95.9 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Total Current Liabilities soared by 22719.36% in 2022 and then crashed by 2446.14% in 2024.
  • Recursion Pharmaceuticals' Total Current Liabilities (Quarter) stood at $46.7 million in 2021, then surged by 114.89% to $100.3 million in 2022, then decreased by 7.08% to $93.2 million in 2023, then soared by 101.21% to $187.5 million in 2024, then decreased by 17.27% to $155.1 million in 2025.
  • Its Total Current Liabilities was $155.1 million in Q3 2025, compared to $164.0 million in Q2 2025 and $142.0 million in Q1 2025.